ZA200900379B - Human endogenous retrovirus polypeptide compositions and methods of use thereof - Google Patents

Human endogenous retrovirus polypeptide compositions and methods of use thereof

Info

Publication number
ZA200900379B
ZA200900379B ZA200900379A ZA200900379A ZA200900379B ZA 200900379 B ZA200900379 B ZA 200900379B ZA 200900379 A ZA200900379 A ZA 200900379A ZA 200900379 A ZA200900379 A ZA 200900379A ZA 200900379 B ZA200900379 B ZA 200900379B
Authority
ZA
South Africa
Prior art keywords
methods
polypeptide compositions
endogenous retrovirus
human endogenous
retrovirus polypeptide
Prior art date
Application number
ZA200900379A
Other languages
English (en)
Inventor
Mario Ostrowski
R Bradley Jones
Seth Rakoff-Nahoum
Douglas Nixon
Keith Garrison
Duncan Meiklejohn
Ashish Agrawal
Jack Lenz
Frederick M Hecht
Original Assignee
Univ California
David Gladstone Inst
Albert Einstein Coll Med
Mario Ostrowski
R Bradley Jones
Seth Rakoff-Nahoum
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, David Gladstone Inst, Albert Einstein Coll Med, Mario Ostrowski, R Bradley Jones, Seth Rakoff-Nahoum filed Critical Univ California
Publication of ZA200900379B publication Critical patent/ZA200900379B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA200900379A 2006-07-21 2007-07-19 Human endogenous retrovirus polypeptide compositions and methods of use thereof ZA200900379B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83246506P 2006-07-21 2006-07-21

Publications (1)

Publication Number Publication Date
ZA200900379B true ZA200900379B (en) 2010-08-25

Family

ID=38957380

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200900379A ZA200900379B (en) 2006-07-21 2007-07-19 Human endogenous retrovirus polypeptide compositions and methods of use thereof

Country Status (15)

Country Link
US (2) US20080171061A1 (pt)
EP (1) EP2046380A4 (pt)
JP (1) JP2009544614A (pt)
KR (1) KR20090060410A (pt)
CN (1) CN101557823A (pt)
AU (1) AU2007275693A1 (pt)
BR (1) BRPI0714714A2 (pt)
CA (1) CA2658393A1 (pt)
IL (1) IL196516A0 (pt)
MX (1) MX2009000659A (pt)
NO (1) NO20090818L (pt)
RU (1) RU2009106089A (pt)
SG (1) SG173997A1 (pt)
WO (1) WO2008011120A2 (pt)
ZA (1) ZA200900379B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9931397B2 (en) 2005-06-27 2018-04-03 Glaxosmithkline Biologicals S.A. Immunogenic composition
US20090297530A1 (en) * 2006-05-22 2009-12-03 Feng Wang-Johanning Herv-k antigens, antibodies, and methods
EP2340851A4 (en) * 2008-09-18 2012-09-26 Univ Keio DIAGNOSTIC METHOD AND THERAPEUTIC METHOD FOR CANCER
US20110250218A1 (en) * 2008-10-29 2011-10-13 Fong Lawrence H Disease-Associated Antigens and Methods of Use Thereof
US20130028933A1 (en) * 2009-12-28 2013-01-31 Ligocyte Pharmaceuticals, Inc. Methods for stabilizing influenza antigen enveloped virus-based virus-like particle solutions
US20120321637A1 (en) * 2011-06-20 2012-12-20 The Board Of Regents Of The University Of Texas System Combination cancer therapy with herv inhibition
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
EP3620794A1 (en) 2012-01-26 2020-03-11 Vanda Pharmaceuticals Inc. Determining a circadian rhythm
WO2014153114A1 (en) * 2013-03-14 2014-09-25 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
US11779603B2 (en) 2016-06-30 2023-10-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HERV-E reactive T cell receptors and methods of use
CN109863165A (zh) * 2016-08-23 2019-06-07 爱姆维恩公司 新型免疫刺激肽
EP3565535A4 (en) 2017-01-05 2020-12-30 Fred Hutchinson Cancer Research Center SYSTEMS AND METHODS FOR IMPROVING THE EFFECTIVENESS OF A VACCINE
JP7457642B2 (ja) * 2017-04-03 2024-03-28 ビオンテック ユーエス インコーポレイテッド タンパク質抗原およびその使用
CN111630060B (zh) * 2017-09-01 2024-01-23 盈珀治疗有限公司 用于在疾病的预防和/或治疗中使用的疫苗
WO2019126186A1 (en) 2017-12-18 2019-06-27 Neon Therapeutics, Inc. Neoantigens and uses thereof
WO2020049169A1 (en) * 2018-09-06 2020-03-12 Centre Léon-Bérard Herv-k-derived antigens as shared tumor antigens for anti-cancer vaccine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092145A1 (en) * 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
AU2002338856A1 (en) * 2001-09-06 2003-03-24 Novimmune S.A. Peptides derived from the superantigen (sag) env protein of herv-k18 and their use in obtaining sag-inhibitory antibodies and in vaccination against sag
AT411262B (de) * 2001-09-27 2003-11-25 Wolff Klaus Dr Humanes endogenes retrovirus
EP1521594B1 (en) * 2001-12-07 2013-10-02 Novartis Vaccines and Diagnostics, Inc. Endogenous retrovirus polypeptides linked to oncogenic transformation
US20040096457A1 (en) * 2001-12-11 2004-05-20 Huber Brigitte T Treatment and prevention of ebv infection and ebv-associated disorders
EP1338606A1 (en) * 2002-02-22 2003-08-27 Magnus Von Knebel Doeberitz Nucleic Acid encoding an HERV-H polypeptide for diagnosing colorectal cancer
US20130108653A1 (en) * 2009-12-22 2013-05-02 Shervin Bahrami Bivalent molecules for hiv entry inhibition
US20120321637A1 (en) * 2011-06-20 2012-12-20 The Board Of Regents Of The University Of Texas System Combination cancer therapy with herv inhibition

Also Published As

Publication number Publication date
IL196516A0 (en) 2011-08-01
US20080171061A1 (en) 2008-07-17
RU2009106089A (ru) 2010-08-27
US20130323279A1 (en) 2013-12-05
MX2009000659A (es) 2009-06-08
NO20090818L (no) 2009-04-17
EP2046380A4 (en) 2013-05-01
KR20090060410A (ko) 2009-06-12
EP2046380A2 (en) 2009-04-15
CA2658393A1 (en) 2008-01-24
JP2009544614A (ja) 2009-12-17
SG173997A1 (en) 2011-09-29
WO2008011120A3 (en) 2008-11-06
CN101557823A (zh) 2009-10-14
WO2008011120A2 (en) 2008-01-24
AU2007275693A1 (en) 2008-01-24
BRPI0714714A2 (pt) 2013-04-09

Similar Documents

Publication Publication Date Title
IL196516A0 (en) Human endogenous retrovirus polypeptide compositions and methods of use thereof
IL262205A (en) Protein formulations and methods for their preparation
IL206978A0 (en) Powdered protein compositions and methods of making same
EP1940460A4 (en) OLIGOD DRO CYTEN MYELIN GLYCOPROTEIN COMPOSITIONS AND USES THEREOF
HK1121420A1 (en) Compositions and methods of use of antibodies against dickkopf-1 and dickkopf-4 dickkopf-1 dickkopf-4
EP2152293A4 (en) PROTEIN DELIVERY COMPOSITIONS AND METHODS OF USING THE SAME
EP2099321A4 (en) Nutmeg compositions and methods for their preparation and use
EP1973986A4 (en) COMPLEX BIOACTIVE COMPOSITIONS AND METHODS OF USE
HRP20160902T1 (hr) Pripravci i postupci uporabe forbolskih estera
EP2102237A4 (en) RECOMBINANT HUMAN FACTOR IX AND USE THEREOF
EP2262469A4 (en) SKIN CARE COMPOSITIONS AND METHODS OF USE
IL195161A0 (en) Pharmaceutical compositions of ropinirole and methods of use thereof
PT2099321T (pt) Composições de leite humano e métodos de fabrico e utilização das mesmas
EP2152304A4 (en) THERAPEUTIC COMPOSITIONS IN NANOEMULSION FORM AND METHOD OF APPLICATION THEREFOR
EP2170404A4 (en) COMPOSITIONS WITH HUMAN EGFR SIRNA AND METHOD OF USE
IL189364A0 (en) Estrogen compositions and therapeutic methods of use thereof
EP1986665A4 (en) COMPOSITIONS DERIVED FROM MICROALGUES FOR IMPROVING HEALTH AND SKIN APPEARANCE
EP2068898A4 (en) BONE CEMENT AND APPLICATION METHOD THEREFOR
EP2064550A4 (en) PRRG4 ASSOCIATED COMPOSITIONS AND METHOD FOR USE THEREOF FOR TUMOR DIAGNOSTIC PROCEDURES
IL197501A0 (en) Modifications of cupredoxin derived peptides and methods of use thereof
IL180907A0 (en) Risedronate compositions and their methods of use
HK1186353A1 (zh) 種製作和使用人體脂肪的組合物的相同方法
PL1890720T3 (pl) Kompozycje farmaceutyczne zawierające peptydy pochodzące z kazeiny i sposoby ich stosowania
EP2234636A4 (en) FORMULATIONS OF STABILIZED PEPTIDES AND PROTEINS
EP2069452A4 (en) ONIUM-HOLDING CMP COMPOSITIONS OF BIOACTIVE COMPLEXES AND METHOD FOR THEIR USE